Pacira BioSciences (FRA:82P) Cyclically Adjusted Revenue per Share: €11.76 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:82P Pacira BioSciences Inc FRA:82P
81 GF Score
Price €21.60
GF Value €25.68
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences Cyclically Adjusted Revenue per Share?

Pacira BioSciences FRA:82P -1.82% 81 Cyclically Adjusted Revenue per Share is €11.76 as of Mar. 2026. GuruFocus rates FRA:82P with a GF Score™ of 81/100 and a GF Value™ of €25.68. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pacira BioSciences's adjusted revenue per share for the three months ended in Mar. 2026 was €3.750. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €11.76 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pacira BioSciences's average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 15.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pacira BioSciences was 19.90% per year. The lowest was 7.20% per year. And the median was 12.75% per year.

As of today (2026-07-15), Pacira BioSciences's current stock price is €21.60. Pacira BioSciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €11.76. Pacira BioSciences's Cyclically Adjusted PS Ratio of today is 1.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pacira BioSciences was 12.28. The lowest was 1.03. And the median was 4.31.


Pacira BioSciences  (FRA:82P) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pacira BioSciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=21.60/11.76
=1.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pacira BioSciences was 12.28. The lowest was 1.03. And the median was 4.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pacira BioSciences Cyclically Adjusted Revenue per Share Related Terms


Pacira BioSciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Cyclically Adjusted Revenue per Share Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.05 8.94 9.65 11.76 10.77

Pacira BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.02 10.40 10.66 10.77 11.76

FRA:82P vs ETON, AMPH, BIOA: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted PS Ratio falls into.


FRA:82P
81GF Score
Pacira BioSciences Inc FRA:82P
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pacira BioSciences's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.75/330.2130*330.2130
=3.750

Current CPI (Mar. 2026) = 330.2130.

Pacira BioSciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.667 241.018 2.284
201609 1.632 241.428 2.232
201612 1.846 241.432 2.525
201703 1.705 243.801 2.309
201706 1.572 244.955 2.119
201709 1.396 246.819 1.868
201712 1.646 246.524 2.205
201803 1.486 249.554 1.966
201806 1.727 251.989 2.263
201809 1.744 252.439 2.281
201812 2.032 251.233 2.671
201903 1.960 254.202 2.546
201906 2.144 256.143 2.764
201909 2.282 256.759 2.935
201912 2.637 256.974 3.389
202003 2.235 258.115 2.859
202006 1.588 257.797 2.034
202009 2.253 260.280 2.858
202012 2.407 260.474 3.051
202103 2.175 264.877 2.711
202106 2.468 271.696 3.000
202109 2.388 274.310 2.875
202112 3.097 278.802 3.668
202203 3.089 287.504 3.548
202206 3.054 296.311 3.403
202209 3.691 296.808 4.106
202212 3.534 296.797 3.932
202303 3.259 301.836 3.565
202306 3.005 305.109 3.252
202309 2.950 307.789 3.165
202312 2.413 306.746 2.598
202403 2.946 312.332 3.115
202406 3.272 314.175 3.439
202409 3.292 315.301 3.448
202412 3.873 315.605 4.052
202503 3.358 319.799 3.467
202506 3.454 322.561 3.536
202509 3.440 324.800 3.497
202512 3.912 324.054 3.986
202603 3.750 330.213 3.750

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €11.76 mean?
Pacira BioSciences (FRA:82P) has a Cyclically Adjusted Revenue per Share of €11.76 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Cyclically Adjusted Revenue per Share too high?
Pacira BioSciences' current Cyclically Adjusted Revenue per Share is €11.76. Overall, Pacira BioSciences has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Cyclically Adjusted Revenue per Share compare to ETON and AMPH?
Pacira BioSciences' Cyclically Adjusted Revenue per Share of €11.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Cyclically Adjusted Revenue per Share is €11.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Cyclically Adjusted Revenue per Share of €11.76. The stock's GF Value™ is €25.68, compared to a current price of €21.60 — trading 15.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €11.76. Pacira BioSciences' overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Cyclically Adjusted Revenue per Share is €11.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €21.60 is trading 15.9% below its estimated GF Value™ of €25.68.

Key valuation signals for FRA:82P:

  • Cyclically Adjusted Revenue per Share: €11.76
  • GF Value™: €25.68 vs. price of €21.60 (15.9% below fair value)
  • GF Score™: 81/100 with 8 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
81GF Score

Get the complete analysis for FRA:82P

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.60
Price
€25.68
GF Value